DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancer

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1Подробнее

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previo...Подробнее

DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancerПодробнее

TUXEDO-1: T-DXd for patients with HER2-positive breast cancer and brain metastasisПодробнее

DESTINY-Breast04: T-DXd for patients with HER2-low mBCПодробнее

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancerПодробнее

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancerПодробнее

DESTINY-Breast15: T-DXd in patients with HR+HR- and HER2-low or HER2 IHC 0 metastatic breast cancerПодробнее

HER2CLIMB-04: tucatinib plus T-DXd for HER2+ breast cancerПодробнее

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroupsПодробнее

Updated analysis of DESTINY-Gastric02: T-DXd in HER2+ GEJ cancer who progressed with trastuzumabПодробнее

DESTINY-Breast06: determining HER2-(ultra)low status in HR+ mBCПодробнее

DESTINY-Breast02: high levels of efficacy of T-DXd in previously treated HER2+ breast cancerПодробнее

#ESMO21 Expert Video Report on HER2-positive metastatic breast cancerПодробнее

Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast CancerПодробнее

Highlights on T-DXd in pretreated HER2-expressing solid tumours : The DESTINY-PanTumor02 studyПодробнее

Efficacy of trastuzumab deruxtecan in HER2-low metastatic breast cancerПодробнее

Treatment strategies for HER2+ metastatic breast cancerПодробнее

Choosing between tucatinib and T-DXd in HER2+ breast cancerПодробнее